===== Opening: Real Consultation Scenario =====
"Doctor, my husband is a carrier of a balanced translocation. Our local doctors recommended PGT-SR. We are looking into Kyrgyzstan. Can they really check for chromosomal structures there? What is the process? Will it be a wasted trip?" — This is an increasingly common type of consultation in reproductive genetics clinics.
===== A Direct Answer to the Question =====PGT-SR Chromosome Screening: Direct Answer
Some reproductive centers in Kyrgyzstan equipped with NGS platforms can perform PGT-SR (Preimplantation Genetic Testing for Chromosomal Structural Rearrangements). This technology is specifically designed for couples where one or both partners are carriers of chromosomal structural abnormalities such as balanced translocations, Robertsonian translocations, and inversions. It screens for embryos with normal chromosomal structures for transfer, reducing the risk of miscarriage and birth defects. The application of PGT-SR in Kyrgyzstan is combined with third-generation IVF technology, requiring a complete cycle including ovarian stimulation, egg retrieval, embryo culture, blastocyst biopsy, NGS genetic analysis, and frozen embryo transfer, taking approximately 2 to 3 months in total.
===== C Doctor's Perspective =====Reproductive Doctor's Perspective: Clinical Value of PGT-SR
From a reproductive medicine standpoint, carriers of chromosomal structural abnormalities have a significantly higher miscarriage rate in natural pregnancies compared to the general population. Taking balanced translocations as an example, about 50% to 70% of the gametes produced by carriers are unbalanced translocations, leading to recurrent miscarriages or severe genetic disorders in embryos. The core value of PGT-SR lies in:
- Improving live birth rate per single transfer — selecting embryos with normal chromosomal structures to avoid repeated implantation failure or miscarriage.
- Reducing the risk of transmitting genetic disorders — blocking deletion/duplication syndromes caused by structural abnormalities.
- Reducing the psychological and financial burden of repeated IVF cycles — although PGT-SR increases upfront costs, it effectively shortens the total time needed to achieve a live birth.
It must be clearly stated: PGT-SR cannot 100% guarantee a completely normal fetus. It primarily screens for known structural abnormalities and cannot detect all genetic issues. Additionally, about 10% to 15% of cycles may be terminated due to the lack of normal embryos available for transfer.
===== L Interpretation of Key Tests =====Key Test Indicators and Report Interpretation
PGT-SR involves two stages of test interpretation:
1. Couple's Chromosome Karyotype Analysis
| Karyotype Result | Clinical Significance | PGT-SR Applicability |
|---|---|---|
| 46,XX,t(2;5)(p21;q31) | Balanced translocation carrier | Strongly recommended PGT-SR |
| 45,XX,der(13;14)(q10;q10) | Robertsonian translocation carrier | Strongly recommended PGT-SR |
| 46,XX,inv(9)(p12q13) | Pericentric inversion (common polymorphism, usually no clinical significance) | Genetic counseling needed; most do not require PGT-SR |
| 46,XX,inv(16)(p13q22) | Pathogenic inversion carrier | PGT-SR recommended |
2. Embryo PGT-SR Test Report
- Chromosomal structure normal (balanced/normal) — can be prioritized for transfer.
- Balanced translocation carrier (same as parent) — embryo phenotype is usually normal, can be transferred, but the offspring may face the same fertility issues in adulthood; this must be disclosed in advance.
- Unbalanced rearrangement (deletion/duplication) — not suitable for transfer; clinical outcome is typically miscarriage or birth defects.
- Inconclusive/amplification failure — result not obtained due to insufficient DNA quality or technical reasons; decision on re-biopsy or discarding depends on embryo morphology.
Actual PGT-SR Process in Kyrgyzstan
The following is a standardized operational pathway; specific details may vary by center:
| Stage | Content | Duration |
|---|---|---|
| 1. Initial Consultation & Genetic Counseling | Submit both partners' chromosome karyotype reports and family genetic history; genetic counselor evaluates PGT-SR indications | 1–2 days |
| 2. Ovarian Stimulation & Egg Retrieval | Standard antagonist protocol or short protocol; transvaginal ultrasound-guided egg retrieval | 10–14 days |
| 3. IVF & Blastocyst Culture | ICSI fertilization (to avoid paternal DNA contamination), culture to blastocyst stage on day 5–6 | 5–6 days |
| 4. Blastocyst Biopsy | Laser drilling to extract 3–5 trophectoderm cells; blastocyst is immediately frozen after biopsy | 1 day |
| 5. Genetic Analysis | Low-coverage whole-genome sequencing on NGS platform to analyze chromosomal copy number variations and structural rearrangements | 10–14 days |
| 6. Frozen Embryo Transfer | Select normal embryo based on genetic results; prepare endometrium via artificial or natural cycle for transfer | 12–16 days |
| 7. Post-Transfer Luteal Support & Pregnancy Test | Progesterone supplementation; blood test for β-hCG 12–14 days after transfer | 14 days |
* The above is the duration for a single cycle. If embryo accumulation or a second stimulation cycle is needed, the total time will be extended accordingly.
===== J Timeline =====Time Planning: From Departure to Transfer
For individuals traveling to Kyrgyzstan for PGT-SR, the following timeline is recommended:
- 2–3 months in advance: Complete pre-tests in home country including both partners' chromosome karyotype, AMH, semen analysis, infectious disease screening, and uterine cavity evaluation; ensure passport validity (at least 6 months remaining).
- Cycle Day 1–14: Arrive on menstrual cycle day 2–3 to start ovarian stimulation (requires stay in Kyrgyzstan for approximately 12–16 days).
- After egg retrieval: Can return home; no need to stay in Kyrgyzstan during embryo biopsy and genetic analysis (about 2 weeks).
- Transfer stage: After receiving the genetic report, arrange to return to Kyrgyzstan for the next menstrual cycle for transfer (stay approximately 7–10 days).
Kyrgyzstan vs. Other Regions: Key Differences
| Dimension | Kyrgyzstan | China (Mainland) | USA / Thailand |
|---|---|---|---|
| Legal Policy | PGT-SR allowed; no restrictions on embryo sex selection (some centers) | Strictly defined indications; requires approval | Varies by state in USA; Thailand has stricter regulations |
| Lab Accreditation | Some centers have international quality control (e.g., CAP, ISO); must verify individually | National Health Commission certified; relatively standardized | Most centers have international accreditation; extensive experience |
| Cost (Single Cycle) | Approximately 80,000–120,000 RMB (including PGT-SR) | Approximately 60,000–100,000 RMB (including PGT-SR, but longer cycles) | 150,000–250,000 RMB |
| Communication & Convenience | Primarily Russian/English; some centers have Chinese coordinators | No language barrier | Primarily English; some Thai centers have Chinese services |
| Suitable For | Translocation carriers seeking a balance of cost-effectiveness and willing to accept moderate cross-border procedures | Families meeting domestic PGT-SR indications who prefer not to travel abroad | Families with high budgets, seeking extensive experience, or needing complex genetic counseling |
Selection Advice: Not all chromosomal structural abnormalities require going abroad. PGT-SR is already well-established in China, but indication review is stricter. Kyrgyzstan can serve as a supplementary option for those restricted by indications or facing long waiting times. The core decision-making factors are: whether the lab has an NGS platform, whether the genetic analysis team is experienced, and whether there is validated data for structural rearrangement analysis algorithms.
===== G Most Easily Overlooked Details =====5 Most Easily Overlooked Details
- ① Timeliness of Parental Karyotype Report: Chromosome karyotype analysis results are valid long-term, but if the patient has undergone radiotherapy, chemotherapy, or bone marrow transplantation, re-sampling is necessary to avoid distorted results.
- ② Timing of Blastocyst Biopsy: PGT-SR must be performed at the blastocyst stage (day 5–6). Cleavage-stage biopsy has been largely phased out due to low DNA amplification success rates.
- ③ Post-biopsy Survival Rate of Frozen Embryos: The survival rate of blastocysts after biopsy and freeze-thaw is about 90%–95%, not 100%. It is important to inquire about the center's data in advance.
- ④ Interpretation of Mosaic Embryos: About 2%–5% of embryos have low-level mosaicism. PGT-SR may miss or inaccurately distinguish these, requiring combined morphological and genetic counseling decisions.
- ⑤ Continuity of Genetic Counseling: Interpretation of PGT-SR reports must be done by a genetic counselor experienced in structural rearrangement analysis. General reproductive doctors may not accurately distinguish between balanced translocation carriers and normal embryos.
Special Situations and Management Strategies
Situation 1: No Normal Embryos Available for Transfer
If all embryos are unbalanced rearrangements, consider: ① Another stimulation cycle to increase the number of embryos and improve the chance of obtaining a normal embryo; ② Egg/sperm donation (must comply with local laws); ③ Attempting transfer of a balanced translocation carrier embryo (requires full informed consent, informing of the offspring's fertility risks in adulthood).
Situation 2: Low Embryo Count (Only 1–2 Blastocysts)
PGT-SR is still recommended because even with only one blastocyst, the probability of it being normal for structural abnormality carriers can reach 20%–30% (depending on the specific rearrangement type). Blind transfer without screening carries a higher risk of miscarriage.
Situation 3: Concurrent Risk of Chromosomal Numerical Abnormalities (e.g., Advanced Maternal Age)
It is recommended to use combined PGT-A + PGT-SR testing. The NGS platform can simultaneously analyze copy number variations (numerical) and structural rearrangements from a single biopsy.
Risk Reminder: Clinical implementation of PGT-SR in Kyrgyzstan has been available for less than 10 years. Biopsy techniques, NGS analysis algorithms, and genetic counseling capabilities vary between centers. Before deciding, it is recommended to request from the center: ① The normal embryo detection rate for PGT-SR in the past 2 years; ② Live birth rate / cumulative live birth rate (not biochemical pregnancy rate); ③ Laboratory international quality control certification documents. Any institution claiming "100% screening accuracy" or "guaranteed success" does not meet industry standards.